Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.37 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22396008 | 0.89 | DGAT1 (0.37) | GBA1DRD2DGAT1MMP2MMP9 | |
| SCHEMBL16645298 | 0.88 | GLS (0.42) | GBA1DRD2DGAT1MMP2MMP9 | |
| SCHEMBL17625567 | 0.85 | MAPK1 (0.39) | GBA1 | |
| SCHEMBL15096376 | 0.83 | GBA1 (0.37) | GBA1DRD2DGAT1MMP2MMP9 | |
| SCHEMBL26770649 | 0.83 | F2RL1 (0.40) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL24450930 | 0.83 | DGAT1 (0.39) | GBA1DRD2DGAT1MMP2MMP9 | |
| SCHEMBL22151452 | 0.83 | DGAT1 (0.39) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL22151451 | 0.83 | DGAT1 (0.39) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL22300339 | 0.83 | GBA1 (0.36) | GBA1DRD2DGAT1MMP2MMP9 | |
| SCHEMBL22909211 | 0.82 | GBA1 (0.42) | GBA1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142803-A1 | NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF | CELULARITY INC. (US) | 2023-05-11 | — | — | US | claimed |
| US-20210379033-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-12-09 | — | — | US | claimed |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | claimed |
| US-10919900-B2 | Aryl hydrocarbon receptor antagonists and uses thereof | Magenta Therapeutics Inc. (US) | 2021-02-16 | — | — | US | claimed |
| US-20200330516-A1 | NATURAL KILLER CELLS AND USES THEREOF | CELULARITY INC. (US) | 2020-10-22 | — | — | US | claimed |
| US-20200123161-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2020-04-23 | — | — | US | claimed |
| US-20190343885-A1 | COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2019-11-14 | — | — | US | claimed |
| US-10457683-B2 | Aryl hydrocarbon receptor antagonists and uses thereof | Magenta Therapeutics Inc. (US) | 2019-10-29 | — | — | US | claimed |
| EP-2788476-B1 | COMPOSITIONS AND METHODS FOR ENHANCED GENERATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS | HUTCHINSON FRED CANCER RES (US) | 2019-05-22 | — | — | EP | claimed |
| EP-2350078-B1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | claimed |
| WO-2017066530-A1 | NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF | ANTHROGENSIS CORPORATION (US) | 2017-04-20 | — | — | WO | claimed |
| US-9580426-B2 | Compounds that expand hematopoietic stem cells | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | claimed |
| WO-2016109661-A1 | NATURAL KILLER CELLS AND USES THEREOF | ANTHROGENESIS CORPORATION (US) | 2016-07-07 | — | — | WO | claimed |
| US-20140369973-A1 | COMPOSITIONS AND METHODS FOR ENHANCED GENERATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-12-18 | — | — | US | claimed |
| EP-2788476-A1 | COMPOSITIONS AND METHODS FOR ENHANCED GENERATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS | Fred Hutchinson Cancer Research Center (US) | 2014-10-15 | — | — | EP | claimed |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-24 | — | — | US | claimed |
| WO-2013086436-A1 | COMPOSITIONS AND METHODS FOR ENHANCED GENERATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2013-06-13 | — | — | WO | claimed |
| EP-2350078-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2011-08-03 | — | — | EP | claimed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | claimed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140369973-A1 | COMPOSITIONS AND METHODS FOR ENHANCED GENERATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS | AHR, NOTCH1, ARNT | GBA1 4237/4885DRD2 2102/4885DGAT1 1637/4885 |
| US-10457683-B2 | Aryl hydrocarbon receptor antagonists and uses thereof | AHR, ARNT, AIPL1 | GBA1 3439/4885DRD2 1749/4885DGAT1 2724/4885 |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | GBA1 349/4885DRD2 4676/4885DGAT1 2259/4885 |
| US-20190343885-A1 | COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | MCL1, HCLS1, KIT | GBA1 1135/4885DRD2 4813/4885DGAT1 1108/4885 |
| US-20200123161-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF | AHR, ARNT, AIPL1 | GBA1 3439/4885DRD2 1749/4885DGAT1 2724/4885 |
| US-20210379033-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | AHR, ARNT, NCOR1 | GBA1 2177/4885DRD2 3095/4885DGAT1 1595/4885 |
| US-10919900-B2 | Aryl hydrocarbon receptor antagonists and uses thereof | AHR, ARNT, AIPL1 | GBA1 3439/4885DRD2 1749/4885DGAT1 2724/4885 |
| US-20200330516-A1 | NATURAL KILLER CELLS AND USES THEREOF | PBK, KLKB1, KLK13 | GBA1 2493/4885DRD2 4647/4885DGAT1 3681/4885 |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | GBA1 349/4885DRD2 4676/4885DGAT1 2259/4885 |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | GBA1 349/4885DRD2 4676/4885DGAT1 2259/4885 |
| US-20230142803-A1 | NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF | PBK, ILF3, IL2 | GBA1 3487/4885DRD2 4807/4885DGAT1 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.